Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome

27 Oct 2016

Abstract excerpt

Mutations in CCAAT/enhancer binding protein (CEBPA) occur in 5-10% of acute myeloid leukemia. CEBPA-double mutated (CEBPA-dm) cases usually bear bi-allelic N- and C-terminal mutations and are associated with favorable clinical outcome. Due to variability of mutation, gene-intrinsic and technical issues, the identification of CEBPA mutants is challenging. Several screening methods (fragment-length analysis, gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27789675
DOI: 10.3324/haematol.2016.153411

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndromePMID 27789675Read ↗

CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.Semantic proximity Read ↗

Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.Semantic proximity Read ↗

Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations.Semantic proximity Read ↗

Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.Semantic proximity Read ↗

Novel insights of acute myeloid leukemia with CEBPA deregulation: Heterogeneity dissection and re-stratification.Semantic proximity Read ↗

Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.Semantic proximity Read ↗

Detection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression array.Semantic proximity Read ↗

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.Semantic proximity Read ↗

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.Semantic proximity Read ↗

Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment.Semantic proximity Read ↗

Prognostic impact of CEBPA mutational subgroups in adult AML.Semantic proximity Read ↗

T/myeloid MPAL with biallelic CEBPA mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.